Form 4: REVB CFO Zygmont Acquires 78,145 Restricted Stock Units

Revelation Biosciences' CFO, Chester S. Zygmont III, acquired 78,145 restricted stock units at $0.90 per share, increasing his indirect beneficial ownership.

Summary

• Chester S. Zygmont III, Chief Financial Officer of Revelation Biosciences, Inc. (REVB), acquired 78,145 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on January 8, 2026, with the RSUs valued at $0.90 per share.
• These RSUs were granted under the company's 2021 Equity Incentive Plan and are scheduled to vest quarterly over two years from the date of grant.
• Following this acquisition, Mr. Zygmont indirectly beneficially owns 473,790 shares through The Zygmont Family Trust Dated October 25, 2016, and 5 shares through Czeslaw Capital Fund, LLC, where he serves as the sole manager.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a key executive generally signals confidence in the company's future prospects and aligns management's interests with shareholders. This is a positive indicator, though it's a compensation-related grant rather than an open market purchase.

Positives

• Increased insider ownership by the Chief Financial Officer signals confidence in the company's future prospects.
• The acquisition of 78,145 Restricted Stock Units aligns management's interests with those of shareholders.
• A two-year quarterly vesting schedule for the RSUs indicates a long-term commitment from the CFO to the company's performance.

Future Outlook

The Restricted Stock Units will vest quarterly over two years from the grant date, indicating a future commitment and aligning the CFO's interests with the company's long-term performance and shareholder value creation.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Increased alignment of management's interests with shareholders due to higher insider ownership and a long-term vesting schedule.
• Employees: May signal stability and confidence from leadership regarding the company's future.

Next Steps

• The 78,145 Restricted Stock Units will vest quarterly over the next two years from the grant date.

Key Dates

Keywords

Revelation Biosciences, REVB, CFO, Insider Transaction, Restricted Stock Units, RSU, Equity Incentive Plan, Beneficial Ownership, Chester Zygmont